Annals of Oncology 14:181-190, 2003
© 2003 European Society for Medical Oncology
Review Article |
The pharmacological treatment of aggressive fibromatosis: a systematic review
1 Social Security Organization Oncology Center; 2 Athens Medical Center, Athens; 3 Saint Anargyri Cancer Center, Kifissia, Greece; 4 The London Bone and Soft Tissue Tumour Service, Meyerstein Institute of Oncology, Middlesex Hospital, London, UK
Received 25 March 2002 ; revised 16 August 2002; accepted 16 September 2002
Abstract
Background:
Despite the use of surgery and radiotherapy, 20–35% of patients with aggressive fibromatosis (AF) will have local recurrence. The purpose of this review was to collect and analyze all available information regarding the role of non-cytotoxic and cytotoxic chemotherapy in AF that has been accumulated over the past few decades.
Patients and methods:
A systematic review of published clinical trials, studies and case series was carried out using the Medline Express Databases and the Cochrane Collaboration Database from 1970 to October 2000.
Results:
Most studies published in the literature are in the form of successful case reports and single-arm series with small patient numbers. Most commonly used agents include hormonal agents, non-steroidal anti-inflammatory drugs (NSAIDs), interferons and cytotoxics. The literature data support the use of hormonal agents. Several questions, however, remain unresolved, such as which is the most suitable endocrine manipulation and what is the optimal dose and duration of treatment. NSAIDs and interferons have demonstrated activity against AF either alone or in combination with hormone therapy or chemotherapy but the precise mechanism of action is still unknown. Finally, there is growing evidence in the literature that chemotherapy is effective against AF with almost one in two patients being likely to respond.
Conclusions:
The evidence in the literature supports the opinion that both non-cytotoxic and cytotoxic chemotherapies are effective against AF. However, the lack of sufficient patient numbers and randomized trials compromises the validity of the reported results and mandates further investigation with properly designed prospective studies including larger patient numbers, with main end points to include not only tumor response rate and survival but also quality-of-life issues.
Key words: aggressive fibromatosis, desmoid tumors, chemotherapy, hormonal therapy
CiteULike 
Connotea 
Del.icio.us What's this?
This article has been cited by other articles:
|
|
 |
|
  P. G. Casali, L. Jost, S. Sleijfer, J. Verweij, J.-Y. Blay, and On behalf of the ESMO Guidelines Working Group Soft tissue sarcomas: ESMO Clinical Recommendations for diagnosis, treatment and follow-up Ann. Onc., May 1, 2009; 20(suppl_4): iv132 - iv136. [Full Text] [PDF]
|
|
|
|
 |
|
 Pathology Quiz Case: Diagnosis Arch Otolaryngol Head Neck Surg, May 1, 2008; 134(5): 560 - 561. [Full Text] [PDF]
|
|
|
|
 |
|
 H F A Vasen, G Moslein, A Alonso, S Aretz, I Bernstein, L Bertario, I Blanco, S Bulow, J Burn, G Capella, et al. Guidelines for the clinical management of familial adenomatous polyposis (FAP) Gut, May 1, 2008; 57(5): 704 - 713. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 H. S. Hosalkar, J. T. Torbert, E. J. Fox, T. F. Delaney, A. J. Aboulafia, and R. D. Lackman Musculoskeletal Desmoid Tumors J. Am. Acad. Ortho. Surg., April 1, 2008; 16(4): 188 - 198. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 H. B. Neuman, E. Brogi, A. Ebrahim, M. F. Brennan, and K. J. Van Zee Desmoid Tumors (Fibromatoses) of the Breast: A 25-Year Experience Ann. Surg. Oncol., January 1, 2008; 15(1): 274 - 280. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 R. Hara, H. Matsuguma, H. Suzuki, Y. Ishikawa, R. Nakahara, T. Yamaguchi, and K. Hirabayashi Desmoid Tumor Presenting as a Superior Sulcus Tumor: A Unique Bone Change in the Vertebral Body Ann. Thorac. Surg., November 1, 2007; 84(5): 1752 - 1754. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S Basu, N Nair, and S Banavali Uptake characteristics of fluorodeoxyglucose (FDG) in deep fibromatosis and abdominal desmoids: potential clinical role of FDG-PET in the management Br. J. Radiol., September 1, 2007; 80(957): 750 - 756. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. Goncalves, G. Monges, Y. Yang, F. Palmerini, P. Dubreuil, T. Noguchi, J. Jacquemier, D. Di Stefano, J.-R. Delpero, H. Sobol, et al. Response of a KIT-positive extra-abdominal fibromatosis to imatinib mesylate and KIT genetic analysis. J Natl Cancer Inst, April 19, 2006; 98(8): 562 - 563. [Full Text] [PDF]
|
|
|
|
 |
|
 Y. Ferah, K. Ayse, C. Mustafa, S. Ugur, G. Murat, and A. I. Lale Possible Therapeutic Role of Vitamin D3 in Aggressive Fibromatosis Jpn. J. Clin. Oncol., August 1, 2004; 34(8): 472 - 475. [Abstract] [Full Text] [PDF]
|
|